Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients

AIDS. 2008 Oct 18;22(16):2212-4. doi: 10.1097/QAD.0b013e328313bf9c.

Abstract

Resistance to CCR5 antagonists can be driven by mutations in gp120. Sequences from 323 anti-CCR5 naive patients were analyzed for the presence of previously described in-vivo or in-vitro resistance mutations to CCR5 antagonists located in the V3 loop of gp120. The V3 loop region was rather polymorphic, and 7.3% of patients showed viruses with combinations of mutations in V3 loop previously described to be involved in maraviroc resistance, a licensed CCR5 antagonist.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • CCR5 Receptor Antagonists*
  • Cyclohexanes / pharmacology
  • Drug Resistance, Viral / genetics*
  • Genotype
  • HIV Envelope Protein gp120 / genetics
  • HIV Fusion Inhibitors / pharmacology*
  • HIV-1 / drug effects*
  • HIV-1 / genetics
  • Humans
  • Maraviroc
  • Mutation
  • Triazoles / pharmacology

Substances

  • CCR5 Receptor Antagonists
  • Cyclohexanes
  • HIV Envelope Protein gp120
  • HIV Fusion Inhibitors
  • Triazoles
  • gp120 protein, Human immunodeficiency virus 1
  • Maraviroc